CL King assumed coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a research report sent to investors on Wednesday, December 27th, MarketBeat reports. The brokerage issued a neutral rating on the biopharmaceutical company’s stock.
A number of other research analysts have also commented on the company. HC Wainwright started coverage on Aratana Therapeutics in a research report on Friday, November 17th. They set a buy rating and a $10.00 price target for the company. Jefferies Group reaffirmed a buy rating and set a $8.00 price target on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Stifel Nicolaus reaffirmed a hold rating and set a $6.00 price target on shares of Aratana Therapeutics in a research report on Monday, December 18th. Zacks Investment Research raised Aratana Therapeutics from a hold rating to a buy rating and set a $7.75 price target for the company in a research report on Thursday, November 9th. Finally, ValuEngine downgraded Aratana Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $8.55.
Shares of Aratana Therapeutics (NASDAQ PETX) opened at $5.29 on Wednesday. Aratana Therapeutics has a 52 week low of $4.81 and a 52 week high of $8.30. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $227.47, a PE ratio of -3.65 and a beta of 3.36.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company had revenue of $6.16 million during the quarter, compared to analyst estimates of $6.47 million. During the same quarter in the previous year, the company posted ($0.38) EPS. Aratana Therapeutics’s revenue for the quarter was up 1440.0% on a year-over-year basis. analysts expect that Aratana Therapeutics will post -1.03 earnings per share for the current year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $6.53, for a total value of $760,849.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.00, for a total value of $350,000.00. Following the completion of the sale, the insider now owns 529,359 shares in the company, valued at approximately $3,705,513. The disclosure for this sale can be found here. Insiders sold a total of 1,057,032 shares of company stock worth $6,186,791 in the last 90 days. 5.20% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of PETX. Janus Henderson Group PLC purchased a new stake in Aratana Therapeutics during the 2nd quarter valued at $12,948,000. Broadfin Capital LLC boosted its stake in Aratana Therapeutics by 40.3% during the 2nd quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock valued at $37,487,000 after purchasing an additional 1,489,500 shares during the last quarter. Franklin Resources Inc. boosted its stake in Aratana Therapeutics by 11.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock valued at $43,462,000 after purchasing an additional 604,518 shares during the last quarter. AWM Investment Company Inc. boosted its stake in Aratana Therapeutics by 49.4% during the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock valued at $11,478,000 after purchasing an additional 525,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Aratana Therapeutics by 197.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock valued at $2,754,000 after purchasing an additional 252,655 shares during the last quarter. Institutional investors and hedge funds own 73.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/12/aratana-therapeutics-petx-receives-new-coverage-from-analysts-at-cl-king.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.